Neoadjuvant radiochemotherapy and response prediction;Neoadjuvante radiochemotherapie und responseprädiktion

Onkologe

Volumn 10, Issue 11, 2004, Pages 1179-1190

  Stuschke, M ^a   Sarbia, M ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Molecular predictors of response; Neoadjuvant radiochemotherapy; p53; Phase II trials; Randomized studies

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MITOMYCIN; PACLITAXEL; PROTEIN P53;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; ESOPHAGUS CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MEDICAL PRACTICE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PREDICTION; PROGNOSIS;

EID: 12144253988     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00761-004-0784-2     Document Type: Article

References (49)

1. Nygaard K, Hagen S, Hansen HS, et al. (1992) Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomised, multicenter study of pre-operative radiotherapy and chemotherapy: the second Scandinavian trial in esophageal carcinoma. World J Surg 16:1104-1110
2. Le Prise E, Etienne PL, Meunier B, et al. (1994) A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 73:1179-1184
3. Apinop C, Puttisak P, Preecha N (1994) A prospective study of combined therapy in esophageal cancer. Heatogastroenterology 41:391-393
4. Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ (1996) A comparisonof multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-7 [Erratum, N Engl J Med 1999;341:384]
5. Bosset JF, Gignoux M, Triboulet JP, et al. (1997) Chemoradiotherapy followed by surgery compared with surgery alone in squamous -cell cancer of the esophagus. N Engl J Med 337:161-167
6. Law S, Kwog D, Tung H, et al (1998) Preoperative chemoradiation for squamous cell esophageal cancer: a prospective randomised trial. Can J Gastroenterol 12:Suppl B:56B, Abstract
7. Walsh T, McDonnell C, Mulligan E, et al. (2000) Multimodal therapy versus surgery alone for squamous cell carcinoma of the esophagus: a prospective randomised trial. Gastroenterology 118 (Suppl 2):1008, Abstract
8. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere Aa, Strawderman M (2001) Randomized trial of preoperative chemoradiotherapy versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19:305-313
9. Burmeister BH, Smithers BM, Fitzgerald L, et al. (2002) A randomized phase III trial of preoperative chemoradiation followed by surgery versus surgery alone for localized resectable cancer of the esophagus. Prog Proc Am Soc Clin Oncol 21:130a.abstract
10. Lee JL, Parl SI, Kim SB, et al. (2004) A single institutional phase III trial of preoperative chemotherapy with hyperfractionated radiotherapy with surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15:947-954
11. Fiorica F, Di Bona D, Schepis F, et al. (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53:925-930
12. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS (2003) Neoadjuvant treatment for respectable cancer of the esophagus and gastroesophageal junction: a meta-analysis of randomised clinical trials. Ann Surg Oncol 10:754-761
13. Urschel JD, Vasan H (2003) A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for respectable esophageal cancer. Am J Surg 185:538-543
14. th en, Vol 1, Cary, NC:851
15. Early Breast Cancer Trialists'Collaborative Group (1990) Treatment of early breast cancer. Vol.1, worldwide evidence 1985-1990. Oxford University Press, Oxford, p 17.
16. Geh JI, Crellin AM, Glynne-Jones R (2001) Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 88:228-256
17. Rice TW, Blackstone EH, Adelstein DJ, et al. (2001) N1 esophageal carcinoma: the importance of staging and downstaging. J Thorac Cardiovasc Surg 121:454-464
18. Geh JI, Bond S.J., Bentzen S.M., et al. (2000) Preoperative Chemoradiotherapy in esophageal Cancer: evidence of dose response. rog Proc Am Soc Clin Oncol 19:958a, Abstract
19. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP (2004) Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22:45-52.
20. Bains MS, Stojadinovic A, Minsky B, et al. (2002) A phase II trial of preoperative combined modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 124:270-277
21. Meluch AA, Hainsworth JD, Gray JR, et al. (1999) Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network Phase II trial. Cancer J Sci Am 5:84-91
22. Adelstein DJ, Rice T, Rybicki LA, et al. (2000) Does paclitaxel improve the chemoradiotherapy of locally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18:2032-2039
23. Wright CD, Wain JC, Lynch TJ, et al. (1997) Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phse I and II study. J Thorac Cardiovasc Surg 114:811-816
24. Ajani JA, Walsh G, Komaki R, et al. (2004) Properative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 100:2347-2354
25. Ilson DH, Bains M, Kelsen DP, et al. (2003) Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 21:2926-2932
26. Denham JW, Steigler A, Kilmurray J, et al. (2003) Relapse pattern after chemo-radiation for carcinoma of the oesophagus. Clin Oncol 15:98-108
27. Van Raemdonck D, van Cutsem E, Menten J, et al. (1997) Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg 11:828-837
28. Wieder HA, Björn LDM, Zimmermann F, et al. (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900-908
29. Kostakoglu L, Goldsmith SL (2004) Pet in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med 45:56-68
30. Forastiere AA, Heitmiller RF, Kleinberg L (1997) Multimodality therapy for esophageal cancer. Chest 112:195S-200S
31. Fisher DE (1994) Apoptosis in cancer therapy: crossing the threshold. Cell 78:539-542
32. Peltenburg LTC (2000) Radiosensitivity of tumor cells - oncogenes and apoptosis. Q J Nucl Med 44:355-364
33. Shah MA, Schwartz GK (2001) Cell cycle mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7:2168-2181
34. Blagosklonny MV (2002) P53: an ubiquitous target of anticancer drugs. Int J Cancer 98:161-166
35. Seitz JF, Perrier H, Monges G, et al (1995) Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53. Gastroenterol Clin Biol 19:465-474
36. Muro K, Ohtsu A, Boku N, et al. (1996) Association of p53 protein expression with responses and survival of patients with locally advanced esophageal carcinoma treated with chemoradiotherapy. Jpn J Clin Oncol 26:65-69
37. Sarbia M, Stahl M, Fink U, et al. (1998) Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 4:2991-2997
38. Krasna MJ, Mao YS, Sonett JR, et al. (1999) P53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann Thorac Surg 68:2021-2024; discussion 2024-2025
39. Ito T, Kaneko K, Makino R, et al. (2001) Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. J Gastroenterol 36:303-311
40. Shimada H, Hoshino T, Okazumi S, et al. (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 86:552-557
41. Kishi K, Doki Y, Miyata H, et al. (2002) Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89:597-603
42. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, et al. (1998) p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer 83:7-18
43. Gibson MK, Abraham SC, Wu TT, et al. (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9:6461-6468
44. Soontrapornchai P, Elsaleh H, Joseph D, et al. (1999) TP53 gene mutation status in pretreatment biopsies of oesophageal adenocarcinoma has no prognostic value. Eur J Cancer 35:1683-1687
45. Hickey K, Grehan D, Reid IM, et al. (1994) Expression of epidermal growth factor receptor and proliferaing cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 75:1693-1698
46. Sarbia M, Stahl M, Fink U et al. (1999) Prognostic significance of Cyclin D1 in esophageal squamous cell carcinoma patients treated by surgery alone or combined therapy modalities. Int J Cancer 84:86-91
47. WAF1 predicts outcome of esophageal cancer patients treated by surgery alone or by combined therapy modalities. Clin Cancer Res 4:2615-2623
48. Harpole DH Jr, Moore MB, Herndon JE et al. (2001) The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 7:562-569
49. Warnecke-Eberz U, Metzger R, Miyazono F, et al. (2004) High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 10:3794-3799